Literature DB >> 7813103

A rare mediastinal tumour presenting with systemic effects due to IL-6 and tumour necrosis factor (TNF) production.

K A Davies1, A P Cope, J B Schofield, C Q Chu, J C Mason, T Krausz, P Smith, A M Denman, M J Walport.   

Abstract

Patients presenting with prolonged systemic illnesses with no specific clinical or serological defining features may be diagnosed as having atypical systemic vasculitides, but often turn out to have occult malignancies. Cytokines have been implicated in causing many of the systemic effects in such cases. In this study we describe a patient presenting after 2 years of a severe systemic illness with a marked acute phase response, due to an occult mediastinal angiomatoid malignant fibrous histiocytoma. Tumour resection was curative. We evaluated in detail the local and systemic production of cytokines induced by this tumour. Blood samples were taken pre- and post-operatively for cytokine studies. In vitro production of IL-2, IL-2R, IL-1 beta, IL-6 and TNF-alpha by cultured monocytes from the patient, as well as plasma cytokine levels, were measured by ELISA. Tumour cytokine production was also evaluated immunocytochemically, and by in situ hybridization with specific cDNA probes. Plasma IL-2R and IL-6, and IL-6 and TNF-alpha production by peripheral blood monocytes were markedly elevated before tumour resection, normalizing post-operatively. Most tumour cells and infiltrating lymphocytes stained with antibodies to IL-6, IL-6R and TNF-alpha, and expressed HLA class II. IL-6 and TNF-alpha mRNA production in the tumour was confirmed by in situ hybridization studies. We have described the first case of an occult angiomatoid malignant fibrous histiocytoma in the mediastinum. Studies of cytokine expression suggested that chronic TNF, IL-6, and IL-2 production by leucocytes and tumour cells in this patient was responsible for the severe systemic illness with which she presented.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7813103      PMCID: PMC1534149          DOI: 10.1111/j.1365-2249.1995.tb03481.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Localized mediastinal lymphnode hyperplasia resembling thymoma.

Authors:  B CASTLEMAN; L IVERSON; V P MENENDEZ
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

2.  Angiomatoid malignant fibrous histiocytoma with extensive lymphadenopathy simulating Castleman's disease.

Authors:  I S Seo; G Frizzera; T D Coates; L D Mirkin; M D Cohen
Journal:  Pediatr Pathol       Date:  1986

3.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

5.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

7.  Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome.

Authors:  M J Costa; S W Weiss
Journal:  Am J Surg Pathol       Date:  1990-12       Impact factor: 6.394

8.  Angiomatoid malignant fibrous histiocytoma: a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm.

Authors:  F M Enzinger
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

9.  Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair.

Authors:  C Q Chu; M Field; S Allard; E Abney; M Feldmann; R N Maini
Journal:  Br J Rheumatol       Date:  1992-10

10.  Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.

Authors:  P Möller; F Momburg; K Koretz; G Moldenhauer; C Herfarth; H F Otto; G J Hämmerling; P Schlag
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

View more
  6 in total

1.  Orthopaedic case of the month: A 14-year-old boy with a medial thigh soft tissue mass.

Authors:  David A Ibrahim; Leo Mascarenhas; Jason P Tovar; Alexandre Arkader
Journal:  Clin Orthop Relat Res       Date:  2013-05       Impact factor: 4.176

2.  Erythropoiesis and erythropoietin synthesis during aseptic acute inflammation.

Authors:  H M Leng; P I Folb
Journal:  Inflamm Res       Date:  1996-11       Impact factor: 4.575

Review 3.  Paraneoplastic rheumatic syndromes.

Authors:  H J Mitnick
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.686

Review 4.  Mesenchymal tumours of the mediastinum--part I.

Authors:  Michael A den Bakker; Alexander Marx; Kiyoshi Mukai; Philipp Ströbel
Journal:  Virchows Arch       Date:  2015-09-10       Impact factor: 4.064

Review 5.  Mesenchymal tumours of the mediastinum--part II.

Authors:  Michael A den Bakker; Alexander Marx; Kiyoshi Mukai; Philipp Ströbel
Journal:  Virchows Arch       Date:  2015-09-10       Impact factor: 4.064

6.  Scapular Angiomatoid Fibrous Histiocytoma with EWSR1-CREB1 Fusion in an Adult Patient.

Authors:  Hiroshi Kobayashi; Naohiro Makise; Aya Shinozaki-Ushiku; Yuki Ishibashi; Masachika Ikegami; Shinji Kohsaka; Tetsuo Ushiku; Katsutoshi Oda; Kiyoshi Miyagawa; Hiroyuki Aburatani; Hiroyuki Mano; Sakae Tanaka
Journal:  Case Rep Orthop       Date:  2021-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.